Horsham, PA, December 2, 2025
Myonex has appointed Chief Financial Officer Greg Lavin as its new Chief Executive Officer, effective January 1, 2026. This strategic leadership transition aims to boost the company’s growth and global expansion, following the retirement of James Lovett, the former CEO. Under Lovett’s tenure, Myonex achieved significant milestones including a new headquarters in Horsham, PA, and various strategic acquisitions. Lavin, with a deep understanding of the clinical research landscape, plans to continue the company’s commitment to client-centric solutions and patient needs.
Myonex Appoints CFO Greg Lavin as CEO, Signaling New Phase of Global Expansion
Horsham, PA – Myonex, a global leader in clinical trial supply and commercial pharmaceutical services, has announced the appointment of Chief Financial Officer Greg Lavin as its new Chief Executive Officer, effective January 1, 2026. This leadership transition marks a strategic move to accelerate the company’s growth and global expansion.
Leadership Transition
Lavin succeeds James Lovett, who is retiring after six years as CEO but will continue to serve on Myonex’s Board of Directors. Under Lovett’s leadership, the company experienced significant growth, including the opening of a 65,000-square-foot global headquarters in Horsham, PA, and the launch of the CTRx program supporting prescription access and localized drug supply for clinical trials. Additionally, Myonex expanded its capabilities through strategic acquisitions in Germany, the United States, and France, enhancing its packaging, distribution, and bioservices operations.
Greg Lavin’s Background
With over six years as Myonex’s CFO, Lavin has been instrumental in transforming the company from a comparator sourcing specialist into a comprehensive clinical supply solutions platform. Before joining Myonex, he served as CFO of QPS Holdings, a contract research organization, where he led integration efforts following multiple global acquisitions. Lavin also held senior financial roles at SDI, Inc. and SDI Health, LLC, both private equity–backed healthcare businesses.
Strategic Vision
Executive Chairman Michael Cohen emphasized Lavin’s deep understanding of client needs and the clinical research ecosystem, positioning him well to lead Myonex into its next phase of expansion. Lavin expressed his commitment to continuing the company’s focus on patient-centric and client-first solutions, leveraging Myonex’s expanded global footprint and diversified service offerings to meet the rising demand in clinical development.
Company Overview
Myonex is a leading global provider of integrated clinical trial supply and commercial pharmaceutical services. The company offers tailored solutions in central and local drug sourcing, packaging, labeling, and ancillary equipment supply to support the specific requirements and complexities of each clinical trial. With locations in the United States, Germany, and the United Kingdom, Myonex partners with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers to deliver flexible and comprehensive solutions for trial supply needs.
Recent Developments
In May 2024, Myonex completed the acquisition of CREAPHARM’s pharmaceutical services business, combining capabilities to serve pharmaceutical and biotech companies in both clinical and commercial stages, including those managing Advanced Therapies. This acquisition expanded Myonex’s services and enhanced its capabilities for clients and the industry, positioning the company to meet the dynamic needs of its clients with agility, flexibility, and reliability.
Looking Ahead
As Lavin steps into the role of CEO, Myonex is poised to build on its current momentum, focusing on expanding its global presence and enhancing its service offerings to support the evolving needs of the clinical trial and pharmaceutical industries.
Frequently Asked Questions (FAQ)
- Who is the new CEO of Myonex?
- Greg Lavin, the current Chief Financial Officer, will assume the role of Chief Executive Officer on January 1, 2026.
- What is the significance of this leadership change?
- The appointment of Greg Lavin as CEO signifies a strategic move to accelerate Myonex’s growth and global expansion, building upon the company’s recent developments and successes.
- What were some of the achievements during James Lovett’s tenure as CEO?
- Under James Lovett’s leadership, Myonex opened a 65,000-square-foot global headquarters in Horsham, PA, launched the CTRx program supporting prescription access and localized drug supply for clinical trials, and expanded its capabilities through strategic acquisitions in Germany, the United States, and France.
- What is Myonex’s core business focus?
- Myonex specializes in integrated clinical trial supply and commercial pharmaceutical services, offering tailored solutions in drug sourcing, packaging, labeling, and ancillary equipment supply to support the specific requirements of each clinical trial.
- What recent acquisition did Myonex complete?
- In May 2024, Myonex completed the acquisition of CREAPHARM’s pharmaceutical services business, expanding its capabilities to serve pharmaceutical and biotech companies in both clinical and commercial stages, including those managing Advanced Therapies.
FAQ Schema in JSON-LD Format
{
"@context": "https://schema.org",
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Who is the new CEO of Myonex?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Greg Lavin, the current Chief Financial Officer, will assume the role of Chief Executive Officer on January 1, 2026."
}
},
{
"@type": "Question",
"name": "What is the significance of this leadership change?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The appointment of Greg Lavin as CEO signifies a strategic move to accelerate Myonex's growth and global expansion, building upon the company's recent developments and successes."
}
},
{
"@type": "Question",
"name": "What were some of the achievements during James Lovett's tenure as CEO?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Under James Lovett's leadership, Myonex opened a 65,000-square-foot global headquarters in Horsham, PA, launched the CTRx program supporting prescription access and localized drug supply for clinical trials, and expanded its capabilities through strategic acquisitions in Germany, the United States, and France."
}
},
{
"@type": "Question",
"name": "What is Myonex's core business focus?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Myonex specializes in integrated clinical trial supply and commercial pharmaceutical services, offering tailored solutions in drug sourcing, packaging, labeling, and ancillary equipment supply to support the specific requirements of each clinical trial."
}
},
{
"@type": "Question",
"name": "What recent acquisition did Myonex complete?",
"acceptedAnswer": {
"@type": "Answer",
"text": "In May 2024, Myonex completed the acquisition of CREAPHARM's pharmaceutical services business, expanding its capabilities to serve pharmaceutical and biotech companies in both clinical and commercial stages, including those managing Advanced Therapies."
}
}
]
}
Key Features of Myonex’s Recent Developments
| Feature | Description |
|---|---|
| Leadership Transition | Appointment of Greg Lavin as CEO, effective January 1, 2026, succeeding James Lovett. |
| Global Headquarters | Opening of a 65,000-square-foot facility in Horsham, PA, enhancing manufacturing and packaging capabilities. |
| CTRx Program | Launch of a program supporting prescription access and localized drug supply for clinical trials. |
| Strategic Acquisitions | Expansion through acquisitions in Germany, the United States, and France, enhancing packaging, distribution, and bioservices operations. |
| CREAPHARM Acquisition | Completion of the acquisition of CREAPHARM’s pharmaceutical services business in May 2024, expanding service offerings. |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE PHILADELPHIA WRITER
The PHILADELPHIA STAFF WRITER represents the experienced team at HEREPhiladelphia.com, your go-to source for actionable local news and information in Philadelphia, Philadelphia County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Mummers Parade, Philadelphia Flower Show, and Thanksgiving Day Parade. Our coverage extends to key organizations like the Greater Philadelphia Chamber of Commerce and United Way of Greater Philadelphia, plus leading businesses in telecommunications, food services, and healthcare that power the local economy such as Comcast, Aramark, and Children's Hospital of Philadelphia. As part of the broader HERE network, we provide comprehensive, credible insights into Pennsylvania's dynamic landscape.
